Your browser doesn't support javascript.
loading
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages.
Hung, Chia-Nung; Chen, Meizhen; DeArmond, Daniel T; Chiu, Cheryl H-L; Limboy, Catherine A; Tan, Xi; Kusi, Meena; Chou, Chih-Wei; Lin, Li-Ling; Zhang, Zhao; Wang, Chiou-Miin; Chen, Chun-Liang; Mitsuya, Kohzoh; Osmulski, Pawel A; Gaczynska, Maria E; Kirma, Nameer B; Vadlamudi, Ratna K; Gibbons, Don L; Warner, Steve; Brenner, Andrew J; Mahadevan, Daruka; Michalek, Joel E; Huang, Tim H-M; Taverna, Josephine A.
Afiliación
  • Hung CN; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Chen M; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • DeArmond DT; Department of Cardiothoracic Surgery, University of Texas Health Science Center, San Antonio, TX, USA.
  • Chiu CH; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Limboy CA; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Tan X; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Kusi M; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Chou CW; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Lin LL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Zhang Z; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Wang CM; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Chen CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA; Office of Nursing Research & Scholarship, School of Nursing, University of Texas Health Science Center, San Antonio, TX, USA.
  • Mitsuya K; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Osmulski PA; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Gaczynska ME; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Kirma NB; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Vadlamudi RK; Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX, USA; Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX, USA.
  • Gibbons DL; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Warner S; Sumitomo Pharma Oncology, Inc, Lehi, UT, USA.
  • Brenner AJ; Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX, USA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Mahadevan D; Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX, USA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
  • Michalek JE; Department of Population Health Sciences, University of Texas Health Science Center, San Antonio, TX, USA.
  • Huang TH; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA; Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX, USA. Electronic address: huangt3@uthscsa.edu.
  • Taverna JA; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA; Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX, USA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio,
Cell Rep ; 42(9): 113067, 2023 09 26.
Article en En | MEDLINE | ID: mdl-37659081
Tumor-associated macrophages (TAMs) are integral to the development of complex tumor microenvironments (TMEs) and can execute disparate cellular programs in response to extracellular cues. However, upstream signaling processes underpinning this phenotypic plasticity remain to be elucidated. Here, we report that concordant AXL-STAT3 signaling in TAMs is triggered by lung cancer cells or cancer-associated fibroblasts in the cytokine milieu. This paracrine action drives TAM differentiation toward a tumor-promoting "M2-like" phenotype with upregulation of CD163 and putative mesenchymal markers, contributing to TAM heterogeneity and diverse cellular functions. One of the upregulated markers, CD44, mediated by AXL-IL-11-pSTAT3 signaling cascade, enhances macrophage ability to interact with endothelial cells and facilitate formation of primitive vascular networks. We also found that AXL-STAT3 inhibition can impede the recruitment of TAMs in a xenograft mouse model, thereby suppressing tumor growth. These findings suggest the potential application of AXL-STAT3-related markers to quantitatively assess metastatic potential and inform therapeutic strategies in lung cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Macrófagos Asociados a Tumores / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Cell Rep Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Macrófagos Asociados a Tumores / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Cell Rep Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos